IRIS VERSICOLOR- iris versicolor root pellet США - англійська - NLM (National Library of Medicine)

iris versicolor- iris versicolor root pellet

washington homeopathic products - iris vers - to relieve the symptoms of headache. indications: iris vers   headache if symptoms persist/worsen or if pregnant/nursing, stop use and consult your practitioner.

IRIS TENAX liquid США - англійська - NLM (National Library of Medicine)

iris tenax liquid

washington homeopathic products - iris tenax - to relieve the symptoms of sleeplessness. indications:  iris tenax   sleeplessness if symptoms persist/worsen or if pregnant/nursing, consult your practitioner.

IRIS VERSICOLOR- iris versicolor root liquid США - англійська - NLM (National Library of Medicine)

iris versicolor- iris versicolor root liquid

washington homeopathic products - iris vers - to relieve the symptoms of headache. indications:  iris vers   headache if symptoms persist/worsen or if pregnant/nursing, consult your practitioner.

SOLIRIS eculizumab (rmc) 300 mg/30 mL concentrated solution for intravenous infusion vial Австралія - англійська - Department of Health (Therapeutic Goods Administration)

soliris eculizumab (rmc) 300 mg/30 ml concentrated solution for intravenous infusion vial

alexion pharmaceuticals australasia pty ltd - eculizumab, quantity: 300 mg - injection, intravenous infusion - excipient ingredients: polysorbate 80; sodium chloride; water for injections; dibasic sodium phosphate heptahydrate; monobasic sodium phosphate monohydrate - soliris is indicated for the treatment of patients with: ? paroxysmal nocturnal haemoglobinuria (pnh) to reduce haemolysis. ? atypical haemolytic uraemic syndrome (ahus). ? adult patients with neuromyelitis optica spectrum disorder (nmosd) who are anti-aquaporin-4 (aqp4) antibody-positive. soliris is not intended for acute treatment of a nmosd relapse.

ULTOMIRIS ravulizumab rch 1100 mg in 11 mL (100 mg/mL) concentrated solution for injection by intravenous infusion vial Австралія - англійська - Department of Health (Therapeutic Goods Administration)

ultomiris ravulizumab rch 1100 mg in 11 ml (100 mg/ml) concentrated solution for injection by intravenous infusion vial

alexion pharmaceuticals australasia pty ltd - ravulizumab, quantity: 100 mg/ml - injection, concentrated - excipient ingredients: monobasic sodium phosphate; dibasic sodium phosphate; polysorbate 80; arginine; sucrose; water for injections - ultomiris is indicated:,? for the treatment of patients with paroxysmal nocturnal haemoglobinuria (pnh),? for the treatment of patients with atypical haemolytic uraemic syndrome (ahus),? as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti-acetylcholine receptor (achr) antibody-positive.,? for the treatment of adult patients with neuromyelitis optica spectrum disorder (nmosd) who are anti-aquaporin 4 (aqp4) antibody-positive.,ultomiris is not intended for the acute treatment of a nmosd relapse.

ULTOMIRIS ravulizumab rch 300 mg in 3 mL (100 mg/mL) concentrated solution for injection by intravenous infusion vial Австралія - англійська - Department of Health (Therapeutic Goods Administration)

ultomiris ravulizumab rch 300 mg in 3 ml (100 mg/ml) concentrated solution for injection by intravenous infusion vial

alexion pharmaceuticals australasia pty ltd - ravulizumab, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: monobasic sodium phosphate; dibasic sodium phosphate; polysorbate 80; arginine; sucrose; water for injections - ultomiris is indicated:,? for the treatment of patients with paroxysmal nocturnal haemoglobinuria (pnh),? for the treatment of patients with atypical haemolytic uraemic syndrome (ahus),? as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti-acetylcholine receptor (achr) antibody-positive.,? for the treatment of adult patients with neuromyelitis optica spectrum disorder (nmosd) who are anti-aquaporin 4 (aqp4) antibody-positive.,ultomiris is not intended for the acute treatment of a nmosd relapse.

SOLIRIS Ізраїль - англійська - Ministry of Health

soliris

alexion pharma israel ltd - eculizumab - concentrate for solution for infusion - eculizumab 10 mg/ml - eculizumab - eculizumab - soliris is indicated for the treatment of patients with: - paroxysmal nocturnal haemoglobinuria (pnh). evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history. eculizumab has not been studied in clinical trials in patients with pnh below 11 years of age.- atypical haemolytic uremic syndrome (ahus).soliris is indicated in adults for the treatment of: - refractory generalized myasthenia gravis (gmg) in patients who are anti-acetylcholine receptor (achr) antibody-positive.-neuromyelitis optica spectrum disorder (nmosd) in patients who are anti-aquaporin-4 (aqp4) antibody-positive with a relapsing course of the disease who have received prior therapy.

Soliris Європейський Союз - англійська - EMA (European Medicines Agency)

soliris

alexion europe sas - eculizumab - hemoglobinuria, paroxysmal - immunosuppressants - soliris is indicated in adults and children for the treatment of:paroxysmal nocturnal haemoglobinuria (pnh).evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history (see section 5.1). atypical haemolytic uremic syndrome (ahus).soliris is indicated in adults for the treatment of:refractory generalized myasthenia gravis (gmg) in patients who are anti-acetylcholine receptor (achr) antibody-positive (see section 5.1).neuromyelitis optica spectrum disorder (nmosd) in patients who are anti-aquaporin-4 (aqp4) antibody-positive with a relapsing course of the disease.

ULTOMIRIS 10 MGML Ізраїль - англійська - Ministry of Health

ultomiris 10 mgml

alexion pharma israel ltd - ravulizumab - concentrate for solution for infusion - ravulizumab 10 mg/ml - ravulizumab - ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with paroxysmal nocturnal haemoglobinuria (pnh): • in patients with haemolysis with clinical symptom(s) indicative of high disease activity. • in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.ultomiris is indicated in the treatment of adult patients with generalized myasthenia gravis (gmg) who are anti-acetylcholine receptor (achr) antibody-positive.